Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC.

Krishnamoorthy GP, Davidson NR, Leach SD, Zhao Z, Lowe SW, Lee G, Landa I, Nagarajah J, Saqcena M, Singh K, Wendel HG, Dogan S, Tamarapu PP, Blenis J, Ghossein R, Knauf JA, R├Ątsch G, Fagin JA.

Cancer Discov. 2018 Oct 10. pii: CD-18-0606. doi: 10.1158/2159-8290.CD-18-0606. [Epub ahead of print]


Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.

Untch BR, Dos Anjos V, Garcia-Rendueles MER, Knauf JA, Krishnamoorthy GP, Saqcena M, Bhanot UK, Socci ND, Ho AL, Ghossein R, Fagin JA.

Cancer Res. 2018 Aug 15;78(16):4642-4657. doi: 10.1158/0008-5472.CAN-17-1925. Epub 2018 May 14.


A Late G1 Lipid Checkpoint That Is Dysregulated in Clear Cell Renal Carcinoma Cells.

Patel D, Salloum D, Saqcena M, Chatterjee A, Mroz V, Ohh M, Foster DA.

J Biol Chem. 2017 Jan 20;292(3):936-944. doi: 10.1074/jbc.M116.757864. Epub 2016 Dec 12.


Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.

Nagarajah J, Le M, Knauf JA, Ferrandino G, Montero-Conde C, Pillarsetty N, Bolaender A, Irwin C, Krishnamoorthy GP, Saqcena M, Larson SM, Ho AL, Seshan V, Ishii N, Carrasco N, Rosen N, Weber WA, Fagin JA.

J Clin Invest. 2016 Nov 1;126(11):4119-4124. doi: 10.1172/JCI89067. Epub 2016 Sep 26.


Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation.

Mukhopadhyay S, Saqcena M, Foster DA.

Oncoscience. 2015 Sep 23;2(10):807-8. eCollection 2015. No abstract available.


Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle.

Saqcena M, Patel D, Menon D, Mukhopadhyay S, Foster DA.

Cell Cycle. 2015;14(14):2285-92. doi: 10.1080/15384101.2015.1046653. Epub 2015 May 6.


Reciprocal regulation of AMP-activated protein kinase and phospholipase D.

Mukhopadhyay S, Saqcena M, Chatterjee A, Garcia A, Frias MA, Foster DA.

J Biol Chem. 2015 Mar 13;290(11):6986-93. doi: 10.1074/jbc.M114.622571. Epub 2015 Jan 29.


Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.

Saqcena M, Mukhopadhyay S, Hosny C, Alhamed A, Chatterjee A, Foster DA.

Oncogene. 2015 May 14;34(20):2672-80. doi: 10.1038/onc.2014.207. Epub 2014 Jul 14.


Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle.

Saqcena M, Menon D, Patel D, Mukhopadhyay S, Chow V, Foster DA.

PLoS One. 2013 Aug 19;8(8):e74157. doi: 10.1371/journal.pone.0074157. eCollection 2013.


High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.

Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, Rodrik-Outmezguine V, Foster DA.

Cell Cycle. 2011 Nov 15;10(22):3948-56. doi: 10.4161/cc.10.22.18124. Epub 2011 Nov 15.


Drosophila insulin and target of rapamycin (TOR) pathways regulate GSK3 beta activity to control Myc stability and determine Myc expression in vivo.

Parisi F, Riccardo S, Daniel M, Saqcena M, Kundu N, Pession A, Grifoni D, Stocker H, Tabak E, Bellosta P.

BMC Biol. 2011 Sep 27;9:65. doi: 10.1186/1741-7007-9-65.


Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s).

Foster DA, Yellen P, Xu L, Saqcena M.

Genes Cancer. 2010 Nov;1(11):1124-31. doi: 10.1177/1947601910392989.


Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1).

Xu L, Salloum D, Medlin PS, Saqcena M, Yellen P, Perrella B, Foster DA.

J Biol Chem. 2011 Jul 22;286(29):25477-86. doi: 10.1074/jbc.M111.249631. Epub 2011 May 28.


Identification of domains responsible for ubiquitin-dependent degradation of dMyc by glycogen synthase kinase 3beta and casein kinase 1 kinases.

Galletti M, Riccardo S, Parisi F, Lora C, Saqcena MK, Rivas L, Wong B, Serra A, Serras F, Grifoni D, Pelicci P, Jiang J, Bellosta P.

Mol Cell Biol. 2009 Jun;29(12):3424-34. doi: 10.1128/MCB.01535-08. Epub 2009 Apr 13.

Supplemental Content

Loading ...
Support Center